urea has been researched along with paclitaxel in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 11 (61.11) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| C -Gaudreault, R; Côté, MF; Deschesnes, RG; Janvier, R; Lacroix, J; Legault, J; Madelmont, JC; Marquis, C; Miot-Noirault, E; Mounetou, E; Petitclerc, E | 1 |
| Feng, J; Jiang, Q; Ren, Y; Sutton, MD; Yang, F; Zhao, J | 1 |
| Inaba, S; Liu, J; Zhou, Y | 1 |
| Bisonni, R; Calvani, M; D'Iddio, S; Graziano, F; Lippe, P; Mancinelli, A | 1 |
| Cohen, RB; Cosgriff, TM; Eisenberg, PD; Hainsworth, JD; Healey, D; Langer, CJ; Liau, K; Madajewicz, S; Pierce, K; Simon, GR; Xu, H | 1 |
| Angove, H; Curry, J; Fazal, L; Lyons, J; Reule, M; Thompson, N; Wallis, N | 1 |
| Böhm, M; Clever, Y; Cremers, B; Schaffner, S; Scheller, B; Speck, U | 1 |
| Babich, JW; Eckelman, WC; Hillier, SM; Joyal, JL; Kern, AM; Maresca, KP; Marquis, JC | 1 |
| Chiappinelli, KB; Goodfellow, PJ; Kizer, NT; Ma, L; Thaker, PH; Trinkaus, KM; Yin, Y | 1 |
| Moawad, EY | 1 |
| Atigh, MK; Christians, U; Erwin, MM; Turner, EA; Yazdani, SK | 1 |
| He, Z; Lv, Q; Wang, Y; Xu, Y; Yang, J; Yang, Z; Zhang, R | 1 |
| Ahmed, J; Bauersachs, J; Berliner, D; Bressollette, E; Cortese, B; Doutrelant, L; Eccleshall, S; Graf, K; Levesque, S; Piraino, D; Roguin, A; Scheller, B; Stella, PR; Widder, JD; Zavalloni, D | 1 |
| Chen, M; Ding, J; Feng, X; Jiang, Z; Wang, Y; Xu, W; Yang, Y | 1 |
| Azar, DA; Chang, GH; Chitalia, VC; Kolachalama, VB; Lyle, C; Shazly, T | 1 |
| Anbalakan, K; Ang, HY; Buist, ML; Leo, HL; Toh, HW | 1 |
| Cao, WG; Guo, JJ; Li, N; Pan, Z; Wang, HX; Wang, JW; Yao, L; Yu, B; Zhang, D; Zhao, SP | 1 |
2 trial(s) available for urea and paclitaxel
| Article | Year |
|---|---|
Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment.
Topics: Acetylcarnitine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carnitine; Chromatography, High Pressure Liquid; Creatinine; Docetaxel; Female; Glucose; Humans; Infusions, Intravenous; Kidney; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Paclitaxel; Phosphates; Taxoids; Urea; Vinblastine; Vinorelbine | 2007 |
A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Exanthema; Female; Gastrointestinal Diseases; Half-Life; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Thiazoles; Treatment Outcome; Urea | 2007 |
16 other study(ies) available for urea and paclitaxel
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance.
Topics: Actins; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Cell Division; Cell Line, Tumor; Cells, Cultured; Chick Embryo; Colchicine; Colonic Neoplasms; Cricetinae; Cytoskeleton; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Endothelium, Vascular; Extracellular Matrix; Humans; Mice; Mice, Inbred BALB C; Microtubules; Paclitaxel; Tubulin; Urea | 2004 |
Parkin stabilizes microtubules through strong binding mediated by three independent domains.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Cell Line; Chromatography; Colchicine; Dimerization; DNA, Complementary; Dose-Response Relationship, Drug; Humans; Microscopy, Fluorescence; Microtubules; Models, Biological; Mutation; Paclitaxel; Protein Binding; Protein Folding; Protein Structure, Tertiary; Salts; Transfection; Tubulin; Ubiquitin-Protein Ligases; Urea | 2005 |
Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment.
Topics: Antibiotics, Antineoplastic; Antimitotic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; Female; gamma-Synuclein; Gene Silencing; Humans; Inhibitory Concentration 50; Neoplasm Proteins; Oncostatin M; Paclitaxel; RNA, Antisense; Time Factors; Transfection; Tumor Stem Cell Assay; Urea | 2006 |
Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; Benzimidazoles; Cell Cycle; Cell Line, Tumor; Collagen Type XI; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Mimosine; Mitosis; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Tumor Suppressor Protein p53; Urea; Xenograft Model Antitumor Assays | 2009 |
Treatment of coronary in-stent restenosis with a novel paclitaxel urea coated balloon.
Topics: Aged; Angioplasty, Balloon, Coronary; Catheters; Coronary Angiography; Coronary Restenosis; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Paclitaxel; Stents; Urea | 2010 |
123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy.
Topics: Animals; Antigens, Surface; Antineoplastic Agents; Cell Count; Cell Line, Tumor; Cell Proliferation; Glutamate Carboxypeptidase II; Glutamates; Humans; Iodine Radioisotopes; Male; Mice; Paclitaxel; Prostatic Neoplasms; Treatment Outcome; Tumor Burden; Urea; Xenograft Model Antitumor Assays | 2011 |
Glycogen synthase kinase 3β inhibition as a therapeutic approach in the treatment of endometrial cancer.
Topics: Adjuvants, Immunologic; Animals; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endometrial Neoplasms; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Lithium Chloride; M Phase Cell Cycle Checkpoints; Mice; Neoplasm Transplantation; Paclitaxel; Signal Transduction; Thiazoles; Urea; Xenograft Model Antitumor Assays | 2013 |
Optimizing and predicting the in vivo activity of AT9283 as a monotherapy and in combination with paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Benzimidazoles; Cell Proliferation; Drug Therapy, Combination; Humans; K562 Cells; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; Paclitaxel; Protein Kinase Inhibitors; Urea; Xenograft Model Antitumor Assays | 2015 |
Coating and Pharmacokinetic Evaluation of Air Spray Coated Drug Coated Balloons.
Topics: Angioplasty, Balloon; Animals; Bioreactors; Cardiovascular Agents; Carotid Arteries; Coated Materials, Biocompatible; Drug Liberation; Excipients; Iohexol; Materials Testing; Paclitaxel; Serum Albumin, Bovine; Surface Properties; Sus scrofa; Tissue Culture Techniques; Tissue Distribution; Urea; Vascular Access Devices | 2018 |
Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Drug Delivery Systems; Drug Liberation; Glutamate Carboxypeptidase II; Glutarates; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Prostate; Prostatic Neoplasms; Urea; Xenograft Model Antitumor Assays | 2018 |
Coronary artery treatment with a urea-based paclitaxel-coated balloon: the European-wide FALCON all-comers DCB Registry (FALCON Registry).
Topics: Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Humans; Paclitaxel; Prospective Studies; Registries; Treatment Outcome; Urea | 2019 |
PEGylated Polyurea Bearing Hindered Urea Bond for Drug Delivery.
Topics: Animals; Cell Death; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Female; Mice, Inbred BALB C; Micelles; Paclitaxel; Polyethylene Glycols; Polymers; Proton Magnetic Resonance Spectroscopy; Urea | 2019 |
Intrinsic coating morphology modulates acute drug transfer in drug-coated balloon therapy.
Topics: Angioplasty, Balloon; Cell Death; Cell Survival; Cells, Cultured; Coated Materials, Biocompatible; Endothelial Cells; Flow Cytometry; Humans; Microscopy, Electron, Scanning; Models, Theoretical; Paclitaxel; Peripheral Arterial Disease; Resins, Plant; Urea | 2019 |
How does the Nature of an Excipient and an Atheroma Influence Drug-Coated Balloon Therapy?
Topics: Angioplasty, Balloon; Citrates; Coated Materials, Biocompatible; Excipients; Humans; Paclitaxel; Plaque, Atherosclerotic; Treatment Outcome; Urea | 2022 |
Chemical Components, Biological Activities, and Toxicological Evaluation of the Fruit (Aril) of Two Precious Plant Species from Genus Taxus.
Topics: Administration, Oral; Alanine Transaminase; alpha-Amylases; Animals; Antioxidants; Aspartate Aminotransferases; Cholesterol; Chromatography, High Pressure Liquid; Flavonoids; Fruit; Hypoglycemic Agents; Male; Mice; Phenols; Plant Extracts; Spectrometry, Mass, Electrospray Ionization; Taxus; Terpenes; Toxicity Tests, Acute; Urea | 2017 |